BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry software in Europe

402

BTG Logo (PRNewsFoto/BTG Plc)

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy and facilitate personalised treatment for patients with liver cancer. CE mark certification follows approval for Simplicit90Y in Canada.

BTG, in collaboration with Mirada Medical, have developed Simplicit90Y to be a customised, easy-to-use, dosimetry software developed for rapid Y-90 selective internal radiation therapy workflow. Simplicit90Y provides digital processing, review and reporting of medical images with unique options for data display, quality control, image manipulation and quantification analysis. Together, these features allow for more standardised and consistent dosimetry planning and post-treatment validation, and the ability to personalise treatment for each patient.

“Dosimetry can be a time intensive and complex process and Simplicit90Y simplifies both dosimetry planning and post-treatment validation,” said Etienne Garin, chair and professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, France. “Knowing you can use this intuitive software to help deliver a more personalised treatment for each patient, achieving the best dose of Y-90 radiation to the tumour while minimising exposure to healthy tissue, gives physicians more confidence.”